Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
61 hedge funds and large institutions have $22.8M invested in Sio Gene Therapies Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 17 closing their positions.
36% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $1.09M
12% less capital invested
Capital invested by funds: $25.8M → $22.8M (-$3.05M)
14% less funds holding
Funds holding: 71 → 61 (-10)
50% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 24
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.79M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$542K |
| 3 |
BlackRock
New York
|
+$387K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$146K |
| 5 |
JP Morgan Chase
New York
|
+$42.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.06M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$1.01M |
| 3 |
Morgan Stanley
New York
|
-$682K |
| 4 |
Two Sigma Investments
New York
|
-$576K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$356K |
SIOX Hedge Fund Activity: Q3 2018 in Review
61 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2018, worth a combined $22.8M — down 12% from $25.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SIOX and 7 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 12 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.79M. The largest seller was Millennium Management, cutting an estimated $1.06M.
- 61 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2018, down from 71 in Q2 2018.
- Funds reported $22.8M of Sio Gene Therapies Inc. Common Stock stock for Q3 2018, down 12% quarter-over-quarter.
- 7 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2018 and 17 closed out, a net change of -10 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $1.79M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2018 was Millennium Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2018.